Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chubb
Accenture
McKinsey
Deloitte
Farmers Insurance
Cipla
US Army
Cantor Fitzgerald

Generated: May 22, 2018

DrugPatentWatch Database Preview

OXILAN-350 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Oxilan-350, and when can generic versions of Oxilan-350 launch?

Oxilan-350 is a drug marketed by Guerbet and is included in one NDA.

The generic ingredient in OXILAN-350 is ioxilan. There is one drug master file entry for this compound. Additional details are available on the ioxilan profile page.
Summary for OXILAN-350
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 24
Patent Applications: 508
DailyMed Link:OXILAN-350 at DailyMed
Drug patent expirations by year for OXILAN-350
Synonyms for OXILAN-350
1,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodo-
107793-72-6
5-(N-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-N-(2-hydroxyethyl)-N -(2,3-dihydroxypropyl)-isophthalamide
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[Acetyl(2,3-dihydroxypropyl)amino]-N-(2,3-dihydroxypropyl)-N'-(2-hydroxyethyl)-2,4,6-triiodoisophthalamide
5-[Acetyl(2,3-dihydroxypropyl)amino]-N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
AB01563289_01
AC1L1GM2
AK129829
AKOS016014026
API0003021
AX8134822
BC678009
CAS-107793-72-6
CCG-213210
CCRIS 6727
CHEBI:135884
CHEMBL1201075
CTK8F1279
D02161
DB09135
DR003568
DSSTox_CID_28643
DSSTox_GSID_48717
DSSTox_RID_82913
DTXSID0048717
FT-0627286
HMS3264D15
ioxilan
Ioxilan (JAN/USP/INN)
Ioxilan [USAN:USP:INN]
Ioxilane
Ioxilane [INN-French]
Ioxilanum
Ioxilanum [INN-Latin]
Ioxitol
J-002011
KB-291792
LS-29720
MOLI000985
N-(2,3-Dihdroxypropyl)-N -(2-hydroxyethyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoiosphthalamide
N-(2,3-Dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-N'-(2-hydroxyethyl)-2,4,6-triiodoisophthalamide
N-(2,3-dihydroxypropyl)-N'-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide
NCGC00182070-02
NCGC00182070-03
NSC-760056
NSC760056
OR199480
Oxilan
Oxilan 300
Oxilan-300
Oxilan-300 (TN)
Pharmakon1600-01503838
RT-013348
SCHEMBL25634
SR-01000883963
SR-01000883963-1
Tox21_113127
Tox21_113127_1

US Patents and Regulatory Information for OXILAN-350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet OXILAN-350 ioxilan INJECTABLE;INJECTION 020316-002 Dec 21, 1995 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for OXILAN-350

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Guerbet OXILAN-350 ioxilan INJECTABLE;INJECTION 020316-002 Dec 21, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
Mallinckrodt
Merck
Argus Health
Boehringer Ingelheim
UBS
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.